Lurbinectedin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lurbinectedin: From an Oncology Product to Multiple Endocrine Neoplasia
One-Sentence Summary
The TxGNN model predicts it may be effective for multiple endocrine neoplasia, but no clinical trials and no publications currently support this prediction, so it is a model-only hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report |
| Predicted New Indication | Multiple endocrine neoplasia |
| TxGNN Prediction Score | 0.9944 |
| Evidence Level | L5 |
| Canada Market Status | Approved but not marketed (approvals on record: 1) |
| Number of DINs | 1 (marketed: 0) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Lurbinectedin is generally described as an alkylating-type agent that binds DNA and inhibits oncogenic transcription. This could plausibly be relevant to neuroendocrine tumours, which is the closest link to the predicted indication.
That link is speculative. Multiple endocrine neoplasia is a hereditary tumour syndrome (for example, MEN1 and RET-related forms), and no direct connection to this drug has been shown. The original indication is also not recorded in the Canadian licence data, so the relationship between the original and new indication cannot be assessed.
The other top-ranked predictions are also supported by the model only, with no trials or publications. They include HIV infection, rheumatoid arthritis, amyotrophic lateral sclerosis and cytomegalovirus infection. Several are veterinary or animal-model diseases (feline immunodeficiency, simian immunodeficiency virus, malignant catarrh, infectious bovine rhinotracheitis). Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02520834 | ZEPZELCA | Not specified | Not specified |
Cytotoxicity
Lurbinectedin is an antineoplastic agent that acts on DNA and transcription. Product-specific toxicity data were not available in the compiled data.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (DNA-binding, transcription-inhibiting agent) |
| Myelosuppression Risk | Expected to be significant for a cytotoxic agent of this type. Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count, liver and renal function |
| Handling Protection | Follow cytotoxic drug handling regulations |
Safety Considerations
Drug Interactions: The interaction screening returned 100 interacting drugs. The Major-level interactions among those listed include:
- Aprepitant
- Dexamethasone
- Clarithromycin
- Cobicistat
- Deferiprone
- Samarium (153Sm) lexidronam
- Lumacaftor
Moderate-level interactions include cimetidine, naltrexone, clotrimazole, ticagrelor, ivacaftor, mercaptopurine and others. Levofloxacin is Minor. Several Major interactions involve drugs that commonly accompany chemotherapy, such as antiemetics and corticosteroids, so co-medication needs careful review.
For warnings and contraindications, please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (Evidence Level L5), with no clinical trials or publications. The mechanism is speculative, and the toxicity profile of a cytotoxic agent adds to the uncertainty of the benefit-risk balance.
To proceed, the following is needed:
- The Health Canada package insert, including approved indication, warnings and contraindications, which blocks safety screening
- Detailed mechanism of action data
- Preclinical or clinical evidence in multiple endocrine neoplasia or related neuroendocrine tumours
- A review of the Major drug interactions against likely co-medications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.